Stock Financial Ratios, Dividends, Split History

WMS / Advanced Drainage Systems Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,631.83
Enterprise Value ($M)1,958.53
Book Value ($M)307.60
Book Value / Share5.44
Price / Book5.31
NCAV ($M)-150.98
NCAV / Share-2.67
Price / NCAV-10.81
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 55,696,000
Weighted Average Number Of Diluted Shares Outstanding 56,334,000
Common Stock Shares Outstanding 56,476,000
Common Shares Outstanding 56,562,490
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.10
Return on Assets (ROA)0.06
Return on Equity (ROE)0.29
Balance Sheet (mrq) ($M)
Quick Ratio0.88
Current Ratio2.07
Income Statement (mra) ($M)
Sales Revenue Goods Net1,330,354,000.00
Operating Income88.25
Net Income64.79
Earnings Per Share Diluted0.99
Earnings Per Share Basic1.00
Cash Flow Statement (mra) ($M)
Cash From Operations137.12
Cash from Investing-30.45
Cash from Financing137.12
Identifiers and Descriptors
Central Index Key (CIK)1604028
Related CUSIPS

Split History

Stock splits are used by Advanced Drainage Systems Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

8h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

9h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

United Rentals (URI) to Acquire BakerCorp for $715 Million

2018-07-03 zacks
United Rentals, Inc. (URI - Free Report) has agreed to acquire BakerCorp. International Holdings Inc. for $715 million. The all-cash deal, slated to close in third-quarter 2018, will give a significant boost to United Rentals’ specialty rental business in North America as well as enable it to foray into some European markets. United Rentals’ shares closed Monday at $144.75, down nearly 2% from Friday’s closing price. (1-0)

Dividend Champions For July 2018

2018-07-02 seekingalpha
The Dividend Champions list is a monthly publication tracking companies with a history of consistently increasing their dividends. Wider in scope than the well-known S&P 500 Dividend Aristocrats and Nasdaq Dividend Achievers, the Dividend Champions covers all companies listed on exchanges in the United States. In order to be included in the list, the annual split-adjusted dividend payout of a company (based on calendar year) must be consistently increasing. (24-0)

Advanced Drainage Systems, Inc. (WMS) CEO Scott Barbour on Q4 2018 Results - Earnings Call Transcript

2018-05-29 seekingalpha
Advanced Drainage Systems, Inc. (NYSE:WMS) Q4 2018 Earnings Conference Call May 29, 2018 10:00 AM ET (6-0)

Advanced Drainage Systems 2018 Q4 - Results - Earnings Call Slides

2018-05-29 seekingalpha
The following slide deck was published by Advanced Drainage Systems in conjunction with their 2018 Q4 earnings call. (2-0)

New Strong Buy Stocks for April 3rd

2018-04-03 zacks
Advanced Drainage Systems, Inc. (WMS - Free Report) : This manufacturer of thermoplastic corrugated pipes and related water management products has seen the Zacks Consensus Estimate for its current year earnings increasing 27.9% over the last 60 days. (2-0)

CUSIP: 00790R104